PharmaCyte Biotech (PMCB) Cash & Equivalents (2012 - 2026)

PharmaCyte Biotech (PMCB) has reported Cash & Equivalents for 15 consecutive years, with $18.6 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 22.62% year-over-year to $18.6 million; the TTM figure through Apr 2026 stood at $18.6 million (up 22.62% YoY), while the FY2026 annual figure was $18.6 million, up 22.62% from the prior year.
• Cash & Equivalents eased to $18.6 million in Q2 2026 per PMCB's latest filing, from $20.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $86.6 million in Q1 2022 and bottomed at $13.2 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $49.1 million across 5 years, with a median of $55.7 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 8471.89% — and 2025, when it sank 73.23%.
• PharmaCyte Biotech's Cash & Equivalents stood at $77.0 million in 2022, then slipped by 4.6% to $73.4 million in 2023, then tumbled by 71.62% to $20.8 million in 2024, then fell by 26.07% to $15.4 million in 2025, then grew by 20.76% to $18.6 million in 2026.
• Business Quant data shows PMCB's Cash & Equivalents at $18.6 million in Q2 2026, $20.2 million in Q1 2026, and $15.4 million in Q4 2025.